Clinical trials: General Medicine
Generalized Anxiety Disorder
Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder
The purpose of this study is to find out how an anti-anxiety drug or placebo affects the activity of your brain when you are at rest and when you are viewing emotional material, such as, emotional faces and pictures.
- Trial name
- GAD (NCT00662259)
- Testing
- Alprazolam (Xanax)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Diego
Drug Resistant Epilepsy, Drop Seizures
Novel Helmet Design in Patients With Seizures
This is a two-part study that aims to determine the reliability and safety of the use of the Hövding inflatable helmet in seizures, as evidenced by the deployment of the helmet during seizures, and qualitative patient reporting.
- Conditions
- Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure
- Trial name
- NCT03443388
- Testing
- Hövding inflatable helmet
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Michael A. Gelfand, MD, PhD
Major Depressive Disorder
Transcranial Laser Therapy for Major Depressive Disorder
The purpose of this study is to see if using Transcranial LED Therapy (TLT) using the PhotoMedex's Omnilux NEw-U LED helps improve symptoms of major depressive disorder (MDD).
- Trial name
- ELATED (NCT01538199)
- Testing
- Near-infrared radiation via Transcranial LED Therapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Paolo Cassano
Anxiety Disorders, Generalized Anxiety Disorder
Drug Therapy for Generalized Anxiety Disorder Among the Elderly
This study will determine the efficacy of escitalopram (Lexapro®), an anti-anxiety drug, for generalized anxiety disorder (GAD) and the ways genetics affect response to treatment for GAD in elderly individuals.
- Trial name
- NCT00105586
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- University of Pittsburgh
Epilepsy, Partial
Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.
- Trial name
- NCT00152451
- Testing
- Seletracetam (ucb 44212)
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- UCB S.A. - Pharma Sector
Hypertension
Effectiveness of SMS Text Reminders to Improve Blood Pressure Among Patients With Hypertension
Objective: To test the primary hypothesis that SMS text messages delivered to patients via mobile phone can improve blood pressure within 12 weeks compared to usual care Design: Parallel group, randomized, controlled trial; the…
- Trial name
- NCT01255436
- Testing
- SMS text reminders, Usual Care
- Where
- Philippines
- Volunteers
- 700 people
- Sponsor
- University of the Philippines
Childhood Absence Epilepsy
Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
The primary purpose of this study is to assess the efficacy of Cannabidiol Oral Solution in the treatment of pediatric participants with treatment-resistant childhood absence seizures.
- Trial name
- NCT03336242
- Testing
- Cannabidiol Oral Solution
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Generalized Anxiety Disorder
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
- Trial name
- NCT00734071
- Testing
- Vortioxetine
- Where
- 33 sites in United States
- Volunteers
- 304 people
- Sponsor
- Takeda
Peripheral Arterial Disease (PAD)
Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease
The objective of this Study is to evaluate the safety and efficacy of the IN.PACT Admiral® drug coated PTA balloon, utilized for the dilatation of the narrowed sections of the artery, as compared to other standard (non drug…
- Trial name
- INPACT SFA I (NCT01175850)
- Testing
- Drug-Coated Balloon (DCB), PTA Balloon: Balloon Angioplasty
- Where
- Germany
- Volunteers
- 331 people
- Sponsor
- Medtronic Endovascular
Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
This non-randomized, interventional study will be conducted in a general practice setting to assess the utility of a benign prostatic enlargement (BPE)/benign prostatic obstruction (BPO) screening tool in conjunction with…
- Trial name
- NCT02757963
- Testing
- Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool
- Where
- 45 sites in France, Germany and 3 more
- Volunteers
- 1,679 people
- Sponsor
- GlaxoSmithKline
Peripheral Arterial Disease
IN.PACT Global Clinical Study
The purpose of this study is to collect safety and efficacy data on the IN.PACT Admiral™ Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral and/or popliteal arteries in a "real world"…
- Trial name
- NCT01609296
- Testing
- IN.PACT Admiral™ Drug Eluting Balloon
- Where
- 65 sites in Argentina, Australia and 25 more
- Volunteers
- 1,535 people
- Sponsor
- Medtronic Endovascular
Type 2 Diabetes Mellitus
Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of sitagliptin/metformin…
- Trial name
- NCT01065766
- Testing
- Sitagliptin/metformin
- Volunteers
- 4,065 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)
Vytorin Reexamination Study (0653A-174)
This survey is conducted for preparing application material for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of VYTORIN through collecting…
- Trial name
- NCT01070966
- Volunteers
- 2,089 people
- Sponsor
- Organon and Co
Osteoporosis
FOSAMAX PLUS and FOSAMAX PLUS D Re-examination Study (0217A-267)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of FOSAMAX PLUS / FOSAMAX PLUS…
- Trial name
- NCT01065779
- Testing
- FOSAMAX PLUS, FOSAMAX PLUS D
- Volunteers
- 880 people
- Sponsor
- Organon and Co
Epilepsy
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Evaluating efficacy \& safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age or greater with idiopathic generalized epilepsy…
- Trial name
- VALOR (NCT02408523)
- Testing
- Lacosamide Tablet, Lasosamide Oral Solution
- Where
- 115 sites in United States, Australia and 20 more
- Volunteers
- 242 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Myasthenia Gravis
A Study of TAK-079 in People With Generalized Myasthenia Gravis
Myasthenia gravis is an autoimmune condition that causes muscle weakness. Autoimmune means the body makes antibodies that attack its own cells and tissues. These types of antibodies are also known as autoantibodies.
- Trial name
- NCT04159805
- Testing
- TAK-079
- Where
- 50 sites in United States, Canada and 4 more
- Volunteers
- 36 people
- Sponsor
- Takeda
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
Type 2 Diabetes
Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01845831
- Testing
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin
- Where
- 5 sites in United States
- Volunteers
- 292 people
- Sponsor
- Emory University
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission
Anxiety in Recovering Opiate Dependence
This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence.
- Conditions
- Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment
- Trial name
- NCT00668265
- Testing
- Quetiapine
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Medical Center